Radiopharmaceuticals receptor-based

In the last decade, a large number of radiolabeled small biomolecules have been studied for their potential as radiopharmaceuticals for diagnosis and radiotherapy of various diseases. This review wiU focus on some fundamental aspects of receptor-based diagnostic radiopharmaceuticals, including radiopharmaceutical design, receptors and receptor imaging, choice of biomolecule, and modification of pharmacokinetics. 

Fig. 2. Selected receptor-based radiopharmaceuticals using the bifunctional approach...

Receptor-Based Radiopharmaceuticals and Molecular Nuclear Medicine... 

In the last chapter receptor-based diagnostic radiopharmaceuticals are reviewed including considerations on drug design, on receptors, and on receptor imaging with the objective of modifying the pharmacokinetics of these agents. 

M.R. Kilboum, M.J. Welch, Fluorine-18 labeled receptor based radiopharmaceuticals, Appl. Radiat. Isot. 37 (1986) 677-683. 

The synthesis of fluorine-18-labelled receptor-based radiopharmaceuticals carried out before 1986 have been reviewed331 and the methods applied for the synthesis of 18F-butyrophenone neuroleptics such as spiroperidol (spiperone), haloperidol have been critically evaluated. The synthesis for preparing 7V-(2-[18F]fluoroethyl)spiperone330 involving the [18F]fluoride ion displacement of a suitable leaving group on the ethyl side chain was found to be particularly good (>50% yield). 

Solublizing agents are surfactants that help to increase dissolution of the lipophilic drug intermediate (the BFC-BM conjugate for receptor-based radiopharmaceuticals) so that a maximal amount of BFC-BM is available for the formation of the 99mTc radiopharmaceutical. Solublizing agents also... 

Leiserowitz L, see Weissbuch I (2005) 259 123-165 Lhotak P (2005) Anion Receptors Based on Calixarenes. 255 65-95 Li WP, Meyer LA, Anderson CJ (2005) Radiopharmaceuticals for Positron Emission Tomography Imaging of Somatostatin Receptor Positive Tumors. 252 179-192 Liang Z, see Du Q (2005) 261 45-61 Lingerfelt L, see Guiseppi-Elie A (2005) 260 161-186... 

W.C. Eckelman. Clinical potential of receptor based radiopharmaceuticals, in Radiopharmaceuticals Progress and clinical Perspectives. Vol. II, Ed. A.R. Fritzberg. CRC. Boca Raton, Florida, pp, 89-113 (1986)... 

Guo W, Hinkle GH, Lee RJ. Tc-HYNIC-folate a novel receptor-based targeted radiopharmaceutical for tumor imaging. J Nucl Med 1999 40 1563 1569. 

Due to the clinical availability of Octreoscan , the first peptide-based receptor-imaging radiopharmaceutical, there has been much interest in the development of a complimentary therapeutic radiopharmaceutical.89... 

---